Goldman says this biotech stock will be a winner thanks to a one-of-a-king treatment

Hemab Therapeutics will likely see more upside in the wake of its recent public listing due to its progress toward developing the first treatment for a pair of rare bleeding disorders, according to Goldman Sachs. The investment bank, which was one of the company's IPO underwriters, initiated coverage of the biotechnology name with a buy rating. It also put a $36 price target on shares, implying 39% upside from Friday's close. "Our Buy rating is driven by sutacimig's potential to dominate [a few rare bleeding disorder therapy] markets as the solo treatment option and HMB-002 having … potential in a large [Von Willebrand disease] market," analyst Richard Law said Tuesday in a note to clients. Hemab went public on May 4, pricing its IPO at $18. The stock doubled that day, hitting a high of $36.61. Since then, it has traded within a $23 to $29 range. On Tuesday, it popped 7% to around $27.75 as Goldman and other Wall Street shops assigned bullish ratings on shares. One-of-a-kind therapy Hemab aims to treat Glanzmann's thrombasthenia and Factor VII deficiency, two very rare inherited bleeding conditions that inhibit blood clotting, with its trial-stage therapy called sutacimig, according to Law. There are currently no other treatments being developed to treat GT and FVIID, meaning Hemab can aim to entirely capture both markets with sutacimig. …